Andrew McConaghie is a Senior Writer at Informa. He specializes in medicine and healthcare, with a focus on healthcare technology, diagnostics, and medical equipment innovations, as well as topics related to consumer health and alternative medicine. His work has been featured in Citeline and other prominent publications.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Andrew McConaghie's articles primarily focus on the healthcare and pharmaceutical industries, with a particular emphasis on scientific advancements, drug development, and industry-specific announcements. His coverage attributes indicate a reliance on press releases and data citations.
Given his focus, Andrew is likely to be interested in pitches from individuals with expert knowledge in pharmaceuticals, biopharmaceuticals, drug development processes, CAR-T therapy or immunology. He may also be receptive to pitches related to significant industry-specific announcements or groundbreaking scientific developments within the healthcare sector.
Although no specific geographic focus is mentioned for Andrew’s coverage area, it would still be beneficial for potential sources to have international expertise given the global nature of the pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma's spending spree on the technology?
The specialist pharma company is looking to expand further, and aims to add more to its in-house pipeline across neuroscience, oncology and rare diseases.
By: Jul By, Andrew McConaghie
Argenx chairman and former CEO Tim Van Hauwermeiren believes Europe is not being ambitious enough for its biopharma sector, which otherwise risks being left behind by the US and China.
Competition is fierce between Ionis and Arrowhead in the emerging severe hypertriglyceridemia market, with Phase III readouts, price slashing and patent battles all in the mix. Arrowhead's CEO talks to Scrip about why he thinks new data give his firm an advantage.
By: Andrew McConaghie
A pioneer of first-in-class oral peptide drugs, Protagonist has opted to let big pharma partners bring its first two products to market. CEO Dinesh Patel tells Scrip how it plans to use a rich royalty stream to challenge more injectable immunology and obesity blockbusters with its pills.
The rheumatoid arthritis failure for its TL1A antibody was not unexpected and analysts see the US biotech's attempt to develop two-drug combinations in ulcerative colitis as its best chance in a crowded field.
The Swiss biotech still has big pharma partnerships in Alzheimer's disease but is putting more focus on developing its in-house pipeline, especially in Parkinson's disease
By: Andrew McConaghie
Adapting to the challenges of Most Favored Nation pricing is a top priority in biopharma boardrooms, though the pricing gulf between the US and other developed nations looks impossible to bridge.
By: Andrew McConaghie
Positive topline results from the China-only SANOVO study in first-line patients help underpin Tagrisso's dominance in EGFR-mutated lung cancer treatment
Its initial filing was rejected in April by the FDA's now-departed Vinay Prasad but a new leadership agrees with UniQure that a new sham-controlled trial is not necessary raising hopes that its first product could soon be approaching the market.
